ClinicalTrials.gg
Drug

Donanemab clinical trials

Also written LY3002813 and Kisunla.

studies test it
17
open now
7
in phase 3
7
first study started
2013

How each study uses donanemab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the donanemab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
2 Jul 2024 · KISUNLA · BLA 761248 (FDA, Drugs@FDA)
European Union
24 Sept 2025 · Kisunla · EMEA/H/C/006024 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Donanemab
15

Brand

Kisunla
2

Development codes

LY3002813
12

Studies by the year they started

17 studies that test it; most in 2026 (7)

Studies that test donanemab, by start year
YearStudies
20131
20151
20171
20202
20212
20223
20267

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
5
Phase 3
7
Phase 4
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 14 · Other 3

Eli Lilly and Company (14) · Paul S. Aisen (1) · Michael Rafii, MD, PhD (1) · Banner Health (1)

Often tested with

Tested in the same studies.

AADvac1 (1) · Nivegacetor (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1, 1 in phase 3

Studies that test donanemab, phase 3 first.

Studies

Open first, then newest update. How each study uses donanemab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 17

Given beside what is tested · 1 — donanemab is usual care or a partner of the new treatment

Codes

What other systems call donanemab · ClinicalTrials.gg INT002035

  • MeSH (NLM) C000729112donanemabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 1ADB65P1KKDONANEMABConfirmed FDA, NLM
  • NCI Thesaurus C166484DonanemabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.